{"id":674204,"date":"2023-10-27T19:28:01","date_gmt":"2023-10-27T19:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=674204"},"modified":"2023-10-27T19:28:01","modified_gmt":"2023-10-27T19:28:01","slug":"cardiovascular-calcification-pipeline-clinical-trials-and-key-companies-sanifit-inositec-sanofi-donga-st","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cardiovascular-calcification-pipeline-clinical-trials-and-key-companies-sanifit-inositec-sanofi-donga-st_674204.html","title":{"rendered":"Cardiovascular Calcification  Pipeline, Clinical Trials, and Key Companies &#8211; Sanifit, Inositec, Sanofi, Dong-A ST"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cardiovascular Calcification  Pipeline, Clinical Trials, and Key Companies - Sanifit, Inositec, Sanofi, Dong-A ST\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Cardiovascular Calcification  Pipeline, Clinical Trials, and Key Companies - Sanifit, Inositec, Sanofi, Dong-A ST\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCardiovascular Calcification Pipeline Insight, 2023,\u201d report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(United States, Nevada, Las Vegas), DelveInsight&rsquo;s, <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cardiovascular-calcification-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">&ldquo;<strong>Cardiovascular Calcification Pipeline Insight, 2023<\/strong><\/a>,&rdquo; report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cardiovascular-calcification-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Cardiovascular Calcification&nbsp; Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Over 6+ companies and 6+ pipeline drugs in Cardiovascular Calcification are in various stages of development, and their anticipated acceptance in the Cardiovascular Calcification market would significantly increase market revenue.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Cardiovascular Calcification companies developing novel drug candidates to improve the Cardiovascular Calcification treatment landscape include Sanifit, Inositec, Sanofi, Dong-A ST, and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Cardiovascular Calcification &nbsp; pipeline therapies in various stages of development include SNF 472, INS-3001, and many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cardiovascular Calcification Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cardiovascular calcification is a process in which mineral deposits form in vessel walls and heart valve leaflets and can lead to tissue stiffening, plaque rupture, and heart failure. Several biological processes contribute to cardiovascular calcification, including extracellular vesicle release, matrix remodeling, loss of mineral-deposition inhibition, impaired mineral resorption, oxidative stress, mitochondrial dysfunction, inflammation, and stem and progenitor cell programs. It is a commonly observed but incompletely understood mechanism of increased atherosclerotic plaque instability and accelerated aortic valve stenosis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d4e9fc89e136a04f9d8587ca967ccde9.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cardiovascular Calcification&nbsp; Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>SNF 472: Sanifit<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">SNF472 is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification. Sanifit&rsquo;s SNF 472 blocks calcification, with action independent of Ca\/Phosphate levels.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>INS-3001: Inositec<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">INS-3001 is a cardiovascular calcification inhibitor, based on myo-inositol hexaphosphate (IP6). It is being developed to treat a number of diseases driven by cardiovascular calcification, including aortic valve stenosis. The molecule has demonstrated the ability to significantly inhibit the calcification process in preclinical studies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;Discover more about the emerging Cardiovascular Calcification drugs @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cardiovascular-calcification-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cardiovascular Calcification Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cardiovascular Calcification Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SNF 472: Sanifit<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">INS-3001: Inositec<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NS-3001: Inositec<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cardiovascular Calcification Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Phases<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s Report covers around 33+ products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cardiovascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravitreal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subretinal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Drugs have been categorized under various product types like Mono, Combination and Mono\/Combination.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cardiovascular-calcification-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Scope of the Cardiovascular Calcification Pipeline Report&nbsp;<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Cardiovascular Calcification &nbsp; Companies: Sanifit, Inositec, Sanofi, Dong-A ST and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Cardiovascular Calcification Pipeline Therapies: SNF 472, INS-3001, and many others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find out more about the Cardiovascular Calcification &nbsp; treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cardiovascular-calcification-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cardiovascular Calcification&nbsp; Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Cardiovascular Calcification Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Cardiovascular Calcification Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cardiovascular Calcification Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cardiovascular Calcification Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Cardiovascular Calcification Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cardiovascular Calcification Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cardiovascular Calcification Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cardiovascular Calcification Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Cardiovascular Calcification Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Cardiovascular Calcification Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Cardiovascular Calcification Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cardiovascular Calcification Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cardiovascular Calcification Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Cardiovascular Calcification Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cardiovascular-calcification-pipeline-clinical-trials-and-key-companies-sanifit-inositec-sanofi-donga-st\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cardiovascular-calcification-pipeline-clinical-trials-and-key-companies-sanifit-inositec-sanofi-donga-st\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cCardiovascular Calcification Pipeline Insight, 2023,\u201d report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cardiovascular-calcification-pipeline-clinical-trials-and-key-companies-sanifit-inositec-sanofi-donga-st_674204.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,403,404],"tags":[],"class_list":["post-674204","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=674204"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/674204\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=674204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=674204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=674204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}